Skip to main content
padlock icon - secure page this page is secure

Reduction of Bladder Cancer Cell Growth in Response to hCGβ CTP37 Vaccinated Mouse Serum

Buy Article:

$45.00 + tax (Refund Policy)

The free β-subunit of human chorionic gonadotrophin (hCGβ) is well established as an ectopic product of epithelial tumors. Originally explained as an epi-phenomenon, hCGβ production by many types of carcinoma is increasingly regarded as a significant tumor event. Studies in bladder cancer have shown that hCGβ production, while not diagnostic, is a very good indicator for poor prognosis through correlations with resistance to radiotherapy and rapid metastasis. These clinical findings led to in vitro studies that have shown a direct response to hCGβ by bladder carcinoma cell lines. This response is linked by inhibition of apoptosis to an increase in cell population. More recently, studies on hCGβ as a marker for poor prognosis in other epithelial cancers now suggest that this phenomenon may not be restricted to bladder carcinoma. Thus, ectopic hCGβ represents an ideal target for immunodepletive therapy. Antisera were generated from mice vaccinated with full-length hCGβ carboxy terminal peptide (CTP37) and a truncated region comprising 24 of the amino acids of the CTP (CTP24), expressed on the surface of cowpea mosaic virus (CPMV). The effect of the resultant murine antiseras on bladder carcinoma cell growth in vitro was investigated. When CTP37 antisera, at dilutions of 1:50 and 1:100, were incubated with two hCGβ-producing cell lines, SCaBER and RT112, significant reductions in cell number, up to 43%, were observed. In the bladder cancer cell line T24, which does not produce hCGβ, CTP37 antisera had no growth effects. CTP24 antiserum, like control sera from mice immunized with wild-type CPMV, had no effects on the in vitro growth of any cell lines. This implies that full-length CTP37, but not CTP24, is involved in the oncogenic inhibition of apoptosis by hCGβ. hCGβ CTP37 vaccines are available as well-tested antifertility vaccines in the Third World. They have now been tested on cancer patients. This study is the only in vitro evidence that such a vaccine would have beneficial antitumor effects via immunodepletion mechanisms. We propose that vaccines such as this could be used as an adjuvant therapy in the treatment of hCGβ-producing bladder cancers.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Anticancer treatment; Cystine knot growth factor; Free hCGβ; Poor prognosis; Vaccine development

Document Type: Research Article

Affiliations: Williamson Laboratory, Department of Obstetrics and Gynecology, Barts and The London, Queen Mary School of Medicine, St. Bartholomews Hospital, London, UK

Publication date: 01 December 2002

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more